


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Previously presented) A compound of formula I:



11

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is hydrogen, CHN_2 , R_2 or $-CH_2Y$;

R is an aliphatic group, an aryl group, an aralkyl group, a heterocyclic group, or a heterocyclalkyl group;

Y is an electronegative leaving group;

R^2 is CO_2H , CH_2CO_2H , or esters, amides or isosteres of CO_2H or CH_2CO_2H , thereof;

$$X_2-X_1 \text{ is } N(R^3)-C(R^3) \text{ or } N=C;$$

each R³ is independently selected from hydrogen or C₁₋₆ aliphatic,

Ring C is a fused aryl ring, provided that the fused aryl ring has an unsubstituted carbon atom at the position adjacent to the $-C(O)-N(-)-$ group in ring B that is adjacent to the side chain comprising R^1 ;

n is 0, 1 or 2; and

each methylene carbon in Ring A is optionally and independently substituted by =O, or by one or more halogen, C₁₋₄ alkyl, or C₁₋₄ alkoxy.

Claim 2. (Previously presented) The compound of claim 1 having one or more of the following groups:

- (a) R^1 is $-CH_2Y$ wherein Y is a halogen, OR, SR, or $-OC=O(R)$, wherein R is an aryl group or heterocyclic group;
- (b) R^2 is CO_2H or esters, amides or isosteres of CO_2H thereof;


- (c) X_2-X_1 is $N=C$;
- (d) Ring C is a fused five-membered aromatic ring having zero to two heteroatoms; and
- (e) n is 0 or 1.

Claim 3. (Previously presented) The compound of claim 2 wherein:

- (a) R^1 is $-CH_2Y$ wherein Y is a halogen, OR, SR, or $-OC=O(R)$, wherein R is an aryl group or heterocyclic group;
- (b) R^2 is CO_2H or esters, amides or isosteres of CO_2H thereof;
- (c) X_2-X_1 is $N=C$;
- (d) Ring C is a fused six-membered aromatic ring having zero to two heteroatoms; and
- (e) n is 0 or 1.

Claim 4. (Previously presented) The compound of claim 3 wherein R^1 is $-CH_2Y$ wherein Y is F; R^2 is CO_2H or an ester or amide thereof; X_2-X_1 is $N=C$; Ring C is benzene ring; and n is 0 or 1.

Claim 5. (Previously presented) The compound of claim 1, said compound selected from the compounds:



Example	R^1	R^2	Ring C	n	X_1	X_2
1	CH_2F	CO_2H	Benzo	0	C	N
2	CH_2F	CO_2H	Benzo	1	C	N
3	CH_2F	CO_2H	Benzo	0	C	C-H
4	CH_2F	CO_2H	Benzo	1	C	C-H
5	CH_2F	CO_2H	Benzo	1	N	C=O
6	CH_2F	CO_2H	Pyrazino	1	N	C=O

Claim 6. (Previously presented) A pharmaceutical composition comprising a compound as claimed in any of claims 1-5 and a pharmaceutically acceptable carrier.

Claims 7-8. (Canceled)

Claim 9. (Currently amended) A method for treating a disease or condition selected from ~~uveitis, inflammatory peritonitis, osteoarthritis, pancreatitis, asthma, adult respiratory distress syndrome, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, inflammatory bowel disease, Crohn's disease, psoriasis, atopic dermatitis, graft vs host disease, organ transplant rejection, osteoporosis, myelodysplastic syndrome, multiple myeloma-related bone disorder, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, haemorrhagic shock, sepsis, septic shock, burns, Shigellosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischemia, myocardial ischemia, acute and chronic heart disease, myocardial infarction, congestive heart failure, atherosclerosis, coronary artery bypass graft, spinal muscular atrophy, amyotrophic lateral sclerosis, multiple sclerosis/alepecia, neurological damage due to stroke, ulcerative colitis, traumatic brain injury, spinal cord injury, hepatitis-B, and hepatitis-C, various forms of liver disease, renal disease,~~ comprising administering to a mammal in need of such a treatment a therapeutically effective amount of a compound as claimed in any of claims 1-5.

Claim 10. (Canceled)

Claim 11. (Previously presented) A method of preserving cells, said method comprising the step of bathing the cells in a solution of a compound as claimed in any of claims 1-5.

Claim 12. (Previously presented) A method of preserving an organ for organ transplant or for preserving a blood product, comprising the step of bathing the organ or blood product in a solution of a compound as claimed in any of claims 1-5.

Claims 13-14. (Canceled)